Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „Stivarga“
Suchtreffer
Begriffe & Kennungen
Stivarga
Eintrag öffnenStivarga · 4.1 Therapeutic indications · 1
Eintrag öffnenStivarga · 4.3 Contraindications · 1
Eintrag öffnenStivarga · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Eintrag öffnenStivarga · 4.4 Special warnings and precautions for use · 1
Eintrag öffnenStivarga · 4.5 Interaction with other medicinal products and other forms of interaction · 1
Eintrag öffnenStivarga · 4.5 · 7 Co-administration of a strong UGT1A9 inhibitor (e.g. mefenamic acid, diflunisal, and niflumic acid) during r
Eintrag öffnenStivarga · 4.5 · 8 The concentration-time profile indicates that regorafenib and its metabolites may undergo enterohepatic circ
Eintrag öffnenStivarga · 4.5 · A clinical probe substrate study was performed to evaluate the effect of 14 days of dosing with 160 mg regoraf
Eintrag öffnenStivarga · 4.5 · Administration of ketoconazole (400 mg for 18 days), a strong CYP3A4 inhibitor, with a single dose of regorafe
Eintrag öffnenStivarga · 4.5 · Administration of rifampicin (600 mg for 9 days), a strong CYP3A4 inducer, with a single dose of regorafenib (
Eintrag öffnenStivarga · 4.5 · Antibiotics
Eintrag öffnenStivarga · 4.5 · Bile salt-sequestering agents Regorafenib, M-2 and M-5 are likely to undergo enterohepatic circulation (see se
Eintrag öffnenStivarga · 4.5 · Breast cancer resistance protein (BCRP) and P-glycoprotein substrates Administration of regorafenib (160 mg fo
Eintrag öffnenStivarga · 4.5 · CYP isoform-selective substrates In vitro data indicate that regorafenib is a competitive inhibitor of the cyt
Eintrag öffnenStivarga · 4.5 · Clinical data indicate that regorafenib has no effect on digoxin pharmacokinetics, therefore can be given conc
Eintrag öffnenStivarga · 4.5 · Inhibitors of CYP3A4 and UGT1A9/inducers of CYP3A4 In vitro data indicate that regorafenib is metabolized by c
Eintrag öffnenStivarga · 4.5 · Inhibitors of P-glycoprotein and BCRP/Inducers of P-glycoprotein and BCRP In vitro studies indicate that the a
Eintrag öffnenStivarga · 4.5 · Pharmacokinetic data indicate that regorafenib may be given concomitantly with substrates of CYP2C8, CYP2C9, C
Eintrag öffnenStivarga · 4.5 · This indicates that co-administration of regorafenib may increase the plasma concentrations of other concomita
Eintrag öffnen